A number of investment brokers have recently updated their price targets on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

05/04/2016 – Achillion Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 9 price target on the stock.

02/26/2016 – Achillion Pharmaceuticals, Inc. was upgraded to “outperform” by analysts at Robert W. Baird. They now have a USD 10 price target on the stock.

02/25/2016 – Achillion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 8 price target on the stock.

12/08/2015 – Achillion Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at William Blair. They now have a USD 16 price target on the stock.

11/06/2015 – Achillion Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 8 price target on the stock.

09/08/2015 – Achillion Pharmaceuticals, Inc. was upgraded to “buy” by analysts at UBS. They now have a USD 11.5 price target on the stock.

05/22/2015 – Achillion Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 10 price target on the stock.

05/20/2015 – Achillion Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at JMP Securities. They now have a USD 24 price target on the stock.

05/20/2015 – Achillion Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen.

04/06/2015 – Achillion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 20 price target on the stock.

03/04/2015 – Barclays began new coverage on Achillion Pharmaceuticals, Inc. giving the company a “underweight” rating. They now have a USD 8 price target on the stock.

12/24/2014 – Achillion Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 22.5 price target on the stock.

12/12/2014 – Achillion Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Wells Fargo. They now have a USD 15.5 price target on the stock.

11/10/2014 – Achillion Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 12 price target on the stock.

10/02/2014 – Alpha BioPharma began new coverage on Achillion Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 16 price target on the stock.

The share price of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was down -0.13% during the last day of trading, with a day high of 8.01. 1549920 shares were traded during the last session.

The stock’s 50 day moving average is 8.14 and its 200 day moving average is 8.34. The stock’s market capitalization is 1.08B. Achillion Pharmaceuticals, Inc. has a 52-week low of 5.57 and a 52-week high of 11.05.

View other investors thoughts on Achillion Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.